Collins Stewart Starts Google (GOOG) at Buy; Good Entry Point On Overblown Concerns
Get Alerts GOOG Hot Sheet
Price: $343.54 -0.12%
Rating Summary:
44 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
44 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Collins Stewart initiates coverage on Google (NASDAQ: GOOG) with a Buy. PT $680.
Collins analyst says, "Google should grow at a 17% CAGR for the next 2 years. Key growth drivers are: 1) 14% CAGR growth in global online advertising due to secular shift from offline to online; 2) international search growth driven by growing internet penetration; 3) Google's exposure to high growth pockets of display like online video (YouTube) and ad exchanges (DoubleClick) and 4) incremental search volume from mobile devices. In addition, Android operating system is a $5B+, high margin opportunity that is yet to be monetized...Margin and management-related concerns overblown."
For more ratings news on Google click here and for the rating history of Google click here.
Shares of Google closed at $521.03 yesterday.
Collins analyst says, "Google should grow at a 17% CAGR for the next 2 years. Key growth drivers are: 1) 14% CAGR growth in global online advertising due to secular shift from offline to online; 2) international search growth driven by growing internet penetration; 3) Google's exposure to high growth pockets of display like online video (YouTube) and ad exchanges (DoubleClick) and 4) incremental search volume from mobile devices. In addition, Android operating system is a $5B+, high margin opportunity that is yet to be monetized...Margin and management-related concerns overblown."
For more ratings news on Google click here and for the rating history of Google click here.
Shares of Google closed at $521.03 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Google execs convened 'all-hands' meeting last week to address AI unit reorganizations amid staff concerns - Reuters
- Leerink Starts Ligand Pharma (LGND) at Outperform
- Leerink Starts Freenome Inc. (FRNM) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
Collins StewartSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share